| 1 |
33341662 | Effects of acid and lactone forms of statins on S-warfarin 7-hydroxylation catalyzed by human liver microsomes and recombinant CYP2C9 variants (CYP2C9.1 and CYP2C9.3). | 2021 Feb |
1 |
| 2 |
32729746 | An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. | 2020 Sep |
1 |
| 3 |
30989645 | Enantiospecific Pharmacogenomics of Fluvastatin. | 2019 Sep |
2 |
| 4 |
29368187 | Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers. | 2018 May |
1 |
| 5 |
30363031 | The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. | 2018 Dec |
2 |
| 6 |
28674251 | Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants. | 2017 |
15 |
| 7 |
26058399 | Drug-drug interactions that interfere with statin metabolism. | 2015 |
1 |
| 8 |
24974574 | Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients. | 2014 Jun |
1 |
| 9 |
25280537 | Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report. | 2014 Oct 3 |
1 |
| 10 |
24024895 | CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study. | 2013 Sep |
3 |
| 11 |
21820929 | [Specific considerations on the prescription and therapeutic interchange of statins]. | 2012 Mar-Apr |
1 |
| 12 |
22847201 | Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. | 2012 Aug |
6 |
| 13 |
22941809 | CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers. | 2012 Nov |
3 |
| 14 |
22148003 | Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin. | 2011 Dec |
1 |
| 15 |
20178046 | Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. | 2010 Mar |
1 |
| 16 |
20809476 | Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits. | 2010 Nov |
1 |
| 17 |
19663817 | Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. | 2009 Nov |
1 |
| 18 |
17307149 | 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. | 2007 Apr 6 |
1 |
| 19 |
17513950 | Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line. | 2007 May |
1 |
| 20 |
16388406 | Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. | 2006 Mar |
1 |
| 21 |
16714062 | Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. | 2006 Oct |
1 |
| 22 |
17178259 | Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. | 2006 Dec |
2 |
| 23 |
15205386 | An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. | 2004 Jul |
1 |
| 24 |
15350166 | Fluvastatin and fluvastatin extended release: a clinical and safety profile. | 2004 Sep |
1 |
| 25 |
29793229 | The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. | 2004 Dec |
1 |
| 26 |
12558459 | Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. | 2003 |
1 |
| 27 |
12573493 | Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. | 2003 Feb 17 |
1 |
| 28 |
12822205 | [Drug interactions with antilipemics]. | 2003 Jan-Feb |
1 |
| 29 |
12891229 | Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. | 2003 Aug |
3 |
| 30 |
14558433 | Pharmacological comparison of the statins. | 2003 |
1 |
| 31 |
12036392 | Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. | 2002 |
1 |
| 32 |
12044584 | Pharmacological interactions of statins. | 2002 May |
1 |
| 33 |
11368292 | Clinical pharmacokinetics of fluvastatin. | 2001 |
3 |
| 34 |
11475198 | [Metabolic interactions with statins]. | 2001 Jan 20 |
1 |
| 35 |
10952477 | Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. | 2000 Jun |
3 |
| 36 |
11029845 | HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. | 2000 Sep-Oct |
1 |
| 37 |
10064574 | The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. | 1999 Mar |
4 |
| 38 |
10197301 | The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. | 1999 Apr |
1 |
| 39 |
10665838 | New insights into the pharmacodynamic and pharmacokinetic properties of statins. | 1999 Dec |
1 |
| 40 |
9804052 | Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? | 1998 Oct |
1 |
| 41 |
8737761 | In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. | 1996 |
1 |
| 42 |
7586933 | In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. | 1995 Oct |
2 |